Kairos acquires AI‑designed pan‑EGFR inhibitor from Celyn
Kairos Pharma has entered into binding terms to acquire CL-273, an investigational, reversible, wild-type-sparing pan‑EGFR small‑molecule inhibitor, from Celyn Therapeutics. CL-273 was discovered using a proprietary AI-driven drug discovery platform. It targets the resistant mutations that develop when using EGFR tyrosine kinase inhibitors,… Read More